{"gene":"ACE2","run_date":"2026-06-09T22:02:38","timeline":{"discoveries":[{"year":2002,"finding":"ACE2 (ACEH) is a zinc metallocarboxypeptidase containing an N-terminal signal sequence, a single catalytic domain with zinc-binding motif (HEMGH), a transmembrane region, and a small C-terminal cytosolic domain. It functions as a carboxypeptidase on angiotensin I (cleaving to Ang 1-9) and angiotensin II (cleaving to Ang 1-7), does not hydrolyse bradykinin, and is insensitive to ACE inhibitors. The protein is proposed to have evolved as a chimera of a single ACE-like catalytic domain and a collectrin-like C-terminal domain.","method":"Cloning, functional expression, in vitro enzymatic assays, domain analysis","journal":"Canadian journal of physiology and pharmacology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro enzymatic reconstitution with substrate characterization and domain mutagenesis context, foundational characterization paper replicated across multiple subsequent studies","pmids":["12025971"],"is_preprint":false},{"year":2007,"finding":"ACE2 3D crystal structure was determined, and the enzyme was shown to cleave angiotensin II to angiotensin-(1-7) and to serve as a receptor for SARS and NL63 coronaviruses. ACE2 protein structure and function were validated through knockout and knock-in mouse models.","method":"Crystal structure determination, knockout/knock-in mouse models, enzymatic activity assays","journal":"The Journal of pathology","confidence":"High","confidence_rationale":"Tier 1 / Strong — 3D structure determination combined with genetic models and enzymatic assays, independently replicated","pmids":["17464936"],"is_preprint":false},{"year":2010,"finding":"ACE2 functions as a key SARS-coronavirus receptor and plays a protective role in SARS pathogenesis. ACE2 also functions as an amino acid transporter (homologous to collectrin), explaining the pathogenic role of ACE2 mutations in Hartnup disorder.","method":"Genetic models (ACE2 knockout mice), collectrin homology analysis, amino acid transport assays","journal":"Circulation journal : official journal of the Japanese Circulation Society","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function models with defined phenotypic readouts, single review summarizing multiple experimental studies","pmids":["20134095"],"is_preprint":false},{"year":2011,"finding":"ACE2 heterodimerizes with the neutral amino acid transporter B0AT1 (SLC6A19) in the small intestine, and this association is required for surface expression of B0AT1. In the kidney, ACE2 associates with B0AT3 through its homolog collectrin (Tmem27) in a tissue-specific manner.","method":"Protein interaction studies, surface expression assays, tissue-specific expression analysis","journal":"Channels (Austin, Tex.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical interaction studies with functional consequence (surface expression), single review consolidating experimental findings","pmids":["21814048"],"is_preprint":false},{"year":2020,"finding":"ACE2 protein robustly localizes within the motile cilia of airway epithelial cells in the upper (nasal) and lower (pulmonary) respiratory tract, representing the initial subcellular site of SARS-CoV-2 viral entry. ACE inhibitors or ARBs do not increase ciliary ACE2 expression.","method":"Immunofluorescence, multiplex imaging of banked human tissue, immunohistochemistry across diverse donor panel","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct localization experiment with functional consequence (viral entry site), multiple orthogonal methods, diverse human tissue panel","pmids":["33116139"],"is_preprint":false},{"year":2020,"finding":"ACE2 protein heterodimerizes with B0AT1 (SLC6A19) or SIT1 (SLC6A20) in the small intestine, and these heterodimers can form quaternary structures that serve as binding sites for SARS-CoV-2 spike glycoproteins. ACE2-B0AT1 association is required for surface expression of the transporter and may favor substrate amino acid supply to B0AT1.","method":"Co-immunoprecipitation, structural studies, viral binding assays","journal":"Clinical science (London, England : 1979)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical heterodimerization with functional consequence for transporter surface expression, single lab review","pmids":["33140827"],"is_preprint":false},{"year":2019,"finding":"ACE2 is expressed on GABAergic neurons in the hypothalamic paraventricular nucleus (PVN), where it supports inhibitory GABAergic tone to presympathetic neurons. ACE2 deletion from all neurons reduces inhibitory inputs to presympathetic neurons and increases blood pressure. ADAM17 co-localizes with AT1 receptors on Sim1 neurons and its knockdown prevents acute pressor response to centrally administered angiotensin-II and preserves ACE2 activity during salt-sensitive hypertension.","method":"Conditional neuron-specific knockout mice, primary neuron cultures, photoactivation, blood pressure telemetry, bicuculline pharmacological blockade","journal":"Hypertension (Dallas, Tex. : 1979)","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional knockout mouse models with multiple orthogonal methods (cultures, telemetry, pharmacology, optogenetics), direct mechanistic pathway placement","pmids":["31564162"],"is_preprint":false},{"year":2020,"finding":"EZH2-mediated H3K27me3 at the ACE2 promoter region inhibits ACE2 expression. EZH2 knockout in human embryonic stem cells significantly increases ACE2 expression, confirmed by ChIP-seq showing decreased H3K27me3 and increased H3K27ac signals at the ACE2 promoter.","method":"EZH2 knockout in hESCs, RNA-seq, ChIP-seq, Western blotting","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with ChIP-seq validation of epigenetic marks, single lab with two orthogonal methods","pmids":["32291076"],"is_preprint":false},{"year":2022,"finding":"SARS-CoV-2 infection down-regulates ACE2 by inducing clathrin- and AP2-dependent endocytosis, leading to lysosomal degradation of ACE2. ACE2 knockdown mimics the downstream gene expression pattern of SARS-CoV-2 S-treated cells (activated cytokine signaling associated with respiratory distress). A soluble ACE2 fragment can block this down-regulation and viral infection.","method":"In vivo animal infection model, in vitro cell culture, siRNA knockdown, gene expression profiling, inhibitor studies","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo and in vitro models with mechanistic dissection of endocytic pathway, multiple orthogonal methods","pmids":["36287912"],"is_preprint":false},{"year":2021,"finding":"ACE2 directly binds both PDZ domains of the scaffolding protein NHERF1 via its intracellular C-terminal PDZ-recognition motif. This interaction tethers ACE2 at the membrane, increasing ACE2 membrane residence; disruption of either NHERF1 PDZ core-binding motif or the ACE2 PDZ recognition sequence eliminates binding. Loss of this interaction decreases ACE2 membrane residence and reduces pseudotyped SARS-CoV-2 entry, while ablating NHERF1 interaction accelerated entry, revealing a regulatory role.","method":"Co-immunoprecipitation, proximity ligation assays in human lung and intestine cells, mutagenesis of PDZ motifs, pseudovirus entry assays","journal":"iScience","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct binding demonstrated by Co-IP and proximity ligation, mutagenesis of interaction motifs, functional consequence measured by viral entry assay, multiple orthogonal methods","pmids":["34189428"],"is_preprint":false},{"year":2023,"finding":"Nedd4-2 is an E3 ubiquitin ligase that ubiquitinates ACE2, leading to its down-regulation during angiotensin II-mediated hypertension. Mutation of lysine residues in the C-terminal of ACE2 generates a ubiquitination-resistant mutant (ACE2-5R) with increased activity and resistance to Ang-II-mediated degradation. Expression of ACE2-5R in the bed nucleus of the stria terminalis enhanced GABAergic input to the PVN and reduced hypertension.","method":"Bioinformatics, proteomics, in vitro gain/loss-of-function experiments, site-directed mutagenesis, optogenetics, blood pressure telemetry, pharmacological blockade","journal":"Cardiovascular research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — identified E3 ligase by proteomics, validated interaction in vitro, mutagenesis of ubiquitination sites, in vivo functional rescue, multiple orthogonal methods","pmids":["37161607"],"is_preprint":false},{"year":2022,"finding":"ACE2 pathway (ACE2/Ang-(1-7)/Mas1 receptor axis) is a critical regulator of thermogenesis and energy expenditure. ACE2 is highly expressed in brown adipose tissue (BAT); cold stimulation increases ACE2 and Ang-(1-7) in BAT and serum. Ace2 knockout and Mas1 knockout mice display impaired thermogenesis. Ace2 pathway activates Akt/FoxO1 and PKA pathways, inducing UCP1 expression and mitochondrial activation. Overexpression of Ace2 or Ang-(1-7) infusion ameliorates impaired thermogenesis in obese mice.","method":"Ace2 and Mas1 knockout mice, BAT transplantation, Ace2 overexpression, Ang-(1-7) infusion, pathway analysis (western blotting for Akt/FoxO1, PKA, UCP1)","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models (KO, overexpression), pharmacological rescue, BAT transplantation, mechanistic pathway dissection by western blotting, replicated across multiple models","pmids":["35014608"],"is_preprint":false},{"year":2021,"finding":"ACE2 autoantibodies develop after SARS-CoV-2 infection and inhibit ACE2 enzymatic activity. Plasma from patients with ACE2 antibodies inhibits exogenous ACE2 activity in vitro, and these patients have lower soluble ACE2 activity in plasma despite similar ACE2 protein levels.","method":"ELISA for ACE2 antibodies, in vitro ACE2 activity inhibition assay using patient plasma","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct functional inhibition assay in vitro, single lab, two orthogonal methods (antibody detection + activity assay)","pmids":["34478478"],"is_preprint":false},{"year":2019,"finding":"ACE2 in breast cancer cells inhibits angiogenesis by downregulating VEGFa expression and inactivating phosphorylation of VEGFR2, MEK1/2, and ERK1/2 in HUVECs. ACE2 also inhibits breast cancer cell migration and metastasis in vivo (zebrafish model).","method":"Transwell migration assay, tube formation assay, Western blotting for pathway phosphorylation, zebrafish xenograft model","journal":"Journal of experimental & clinical cancer research : CR","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro functional assays with downstream pathway analysis and in vivo zebrafish validation, single lab","pmids":["31023337"],"is_preprint":false},{"year":2022,"finding":"ACE2 maintains enteral intestinal barrier integrity and reduces diabetic retinopathy (DR) progression through intestinal MasR activation, leading to GSK-3β/c-Myc-mediated decrease in intestinal glucose transporter expression. Genetic overexpression of intestinal ACE2 or oral administration of ACE2-expressing probiotic preserved barrier integrity, reduced inflammation, improved hyperglycemia, and delayed/reversed DR in Akita mice.","method":"Genetic intestinal ACE2 overexpression (Vil-Cre.hAce2KI-Akita mice), probiotic oral delivery of ACE2, pathway analysis (MasR, GSK-3β, c-Myc), gut permeability assays, retinal imaging","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic and pharmacological models, defined downstream pathway (MasR/GSK-3β/c-Myc), functional readouts at gut and eye, replicated with independent approaches","pmids":["36448480"],"is_preprint":false},{"year":2023,"finding":"ACE2 interacts with EGFR; SARS-CoV-2 spike protein activates the EGFR-MAPK signaling axis. A cross-talk exists between ACE2 and EGFR that regulates ACE2 abundance and EGFR activation/subcellular localization. Inhibiting EGFR-MAPK activation reduces SARS-CoV-2 infection.","method":"Co-immunoprecipitation/proximity assays, EGFR inhibitor treatment, pseudotyped particle and authentic SARS-CoV-2 infection assays, Western blotting","journal":"Life science alliance","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal interaction demonstrated, functional consequence tested with authentic virus, single lab with multiple orthogonal methods","pmids":["37402592"],"is_preprint":false},{"year":2005,"finding":"ACE2 mRNA and protein expression increase in the border/infarct area after myocardial infarction (MI) in rats. ACE2 protein localizes to macrophages, vascular endothelium, smooth muscle, and myocytes post-MI. Ramipril (ACE inhibitor) had no effect on cardiac ACE2 mRNA, which remained elevated, suggesting independent regulation of ACE2 from ACE. Immunoreactivity of ACE2 was also increased in failing human hearts.","method":"Quantitative RT-PCR, immunohistochemistry, in vitro autoradiography, ACE2 activity assays, rat MI model, human failing heart specimens","journal":"European heart journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (mRNA, protein, activity), animal model plus human tissue validation, negative result (ACE inhibitor no effect on ACE2) is mechanistically informative","pmids":["15671045"],"is_preprint":false},{"year":2015,"finding":"Apelin is a catalytic substrate for ACE2 in addition to angiotensin II. ACE2 cleaves and degrades apelin peptides, forming part of a negative feedback loop in the apelinergic system.","method":"Enzymatic substrate assays (in vitro cleavage), referenced in review","journal":"International journal of hypertension","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro enzymatic substrate identification referenced in review context, single finding without full methodological detail in abstract","pmids":["25815211"],"is_preprint":false},{"year":2021,"finding":"ACE2 is a carboxypeptidase that degrades angiotensin II, B1-bradykinin, and apelin, acting as a critical regulator of cardiovascular physiology. Both SARS-CoV-2 and SARS coronaviruses downregulate ACE2 expression upon infection, contributing to ARDS pathogenesis.","method":"Review of enzymatic substrate characterization studies, genetic animal models with ARDS phenotype readout","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — enzymatic substrate diversity established across multiple independent labs, ARDS protective role in genetic models","pmids":["35003058"],"is_preprint":false},{"year":2008,"finding":"ACE2 expression and activity are significantly enhanced during pregnancy, with placentas being the major contributors followed by kidney and uterus. Total ACE2 activity increases approximately twofold in pregnancy, consistent with a role in modulating systemic and local uteroplacental hemodynamics.","method":"Quantitative RT-PCR for mRNA, enzymatic activity assays, normotensive and hypertensive rat pregnancy model","journal":"American journal of physiology. Regulatory, integrative and comparative physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative mRNA and activity measurements in animal model, single lab with two orthogonal methods","pmids":["18945956"],"is_preprint":false}],"current_model":"ACE2 is a zinc-dependent monocarboxypeptidase ectoenzyme (type I transmembrane glycoprotein) with an HEMGH zinc-binding motif that cleaves angiotensin II to the vasodilatory angiotensin-(1-7), angiotensin I to Ang 1-9, and also degrades apelin and B1-bradykinin; it is insensitive to classical ACE inhibitors, heterodimerizes with intestinal amino acid transporters (B0AT1/SLC6A19) to regulate their surface expression and neutral amino acid absorption, is tethered at the plasma membrane via interaction of its C-terminal PDZ motif with NHERF1, is ubiquitinated and degraded by the E3 ligase Nedd4-2 (promoted by angiotensin II), and is transcriptionally repressed by EZH2-mediated H3K27me3 at its promoter; it localizes prominently to airway motile cilia, proximal tubular epithelium, brown adipose tissue, and hypothalamic GABAergic neurons where it supports inhibitory tone to presympathetic nuclei; the ACE2/Ang-(1-7)/Mas receptor axis counterbalances the classical ACE/Ang II/AT1R axis in cardiovascular, renal, pulmonary, intestinal, and metabolic homeostasis (including thermogenesis via Akt/FoxO1 and PKA/UCP1 pathways), and serves as the obligate entry receptor for SARS-CoV, SARS-CoV-2, and HCoV-NL63, with viral binding inducing clathrin/AP2-dependent endocytosis and lysosomal degradation of ACE2."},"narrative":{"mechanistic_narrative":"ACE2 is a zinc-dependent monocarboxypeptidase ectoenzyme that anchors a protective arm of the renin-angiotensin system, counterbalancing the classical ACE/Ang II axis across cardiovascular, renal, intestinal, and metabolic tissues [PMID:12025971, PMID:35003058]. Its single catalytic domain carries an HEMGH zinc-binding motif and cleaves angiotensin I to Ang 1-9 and angiotensin II to the vasodilatory angiotensin-(1-7), while remaining insensitive to classical ACE inhibitors; it additionally degrades apelin and B1-bradykinin [PMID:12025971, PMID:25815211, PMID:35003058]. The ACE2/Ang-(1-7)/Mas1 axis drives downstream physiology in several settings: it activates Akt/FoxO1 and PKA signaling to induce UCP1 and brown-adipose thermogenesis [PMID:35014608], maintains intestinal barrier integrity and limits diabetic retinopathy through intestinal MasR/GSK-3β/c-Myc signaling [PMID:36448480], and in hypothalamic PVN GABAergic neurons supports inhibitory tone to presympathetic neurons, restraining blood pressure [PMID:31564162]. As a type I transmembrane glycoprotein, ACE2 is a chimera of an ACE-like catalytic domain and a collectrin-like C-terminal domain, and it heterodimerizes with neutral amino acid transporters B0AT1/SLC6A19 (and SIT1/SLC6A20) to control their surface expression and neutral amino acid absorption [PMID:12025971, PMID:21814048, PMID:33140827]. Its membrane abundance is set post-translationally: a C-terminal PDZ-recognition motif binds the scaffold NHERF1 to tether ACE2 at the surface [PMID:34189428], the E3 ligase Nedd4-2 ubiquitinates C-terminal lysines to drive angiotensin II-promoted degradation [PMID:37161607], and the gene is transcriptionally repressed by EZH2-mediated H3K27me3 at its promoter [PMID:32291076]. ACE2 robustly localizes to airway motile cilia and serves as the obligate entry receptor for SARS-CoV, SARS-CoV-2, and NL63 coronaviruses; viral binding triggers clathrin/AP2-dependent endocytosis and lysosomal degradation of ACE2, and a soluble ACE2 fragment blocks both down-regulation and infection [PMID:17464936, PMID:33116139, PMID:36287912].","teleology":[{"year":2002,"claim":"Established ACE2 as a distinct zinc carboxypeptidase that processes angiotensin peptides but, unlike ACE, is insensitive to ACE inhibitors and does not cleave bradykinin, defining a separate enzymatic arm of the renin-angiotensin system.","evidence":"Cloning, functional expression, in vitro enzymatic assays, and domain analysis","pmids":["12025971"],"confidence":"High","gaps":["Did not resolve the in vivo physiological consequence of Ang 1-7 generation","Substrate repertoire beyond angiotensin peptides not yet defined"]},{"year":2005,"claim":"Showed ACE2 is dynamically regulated and induced in injured myocardium independently of ACE, indicating a tissue-level cardiac protective response distinct from the classical pathway.","evidence":"RT-PCR, immunohistochemistry, activity assays in rat MI model and human failing hearts","pmids":["15671045"],"confidence":"High","gaps":["Mechanism of transcriptional induction after injury not identified","Causal contribution of induced ACE2 to repair vs. fibrosis untested"]},{"year":2007,"claim":"Determined the ACE2 crystal structure and confirmed via genetic models its dual role as Ang II carboxypeptidase and coronavirus receptor, unifying enzymatic and viral-entry functions on one protein.","evidence":"Crystal structure determination plus knockout/knock-in mouse models and enzymatic assays","pmids":["17464936"],"confidence":"High","gaps":["Structural basis of regulated surface trafficking not addressed","Did not connect receptor and enzymatic roles mechanistically"]},{"year":2008,"claim":"Demonstrated physiological up-regulation of ACE2 expression and activity in pregnancy, implicating it in uteroplacental hemodynamic adaptation.","evidence":"RT-PCR and enzymatic activity in normotensive and hypertensive rat pregnancy models","pmids":["18945956"],"confidence":"Medium","gaps":["Signal driving pregnancy-associated induction unknown","Human placental relevance inferred from rat model"]},{"year":2011,"claim":"Defined a non-enzymatic chaperone function: ACE2 heterodimerizes with B0AT1 (and collectrin with B0AT3 in kidney) to enable transporter surface expression, linking ACE2 to neutral amino acid absorption and Hartnup-disorder pathology.","evidence":"Protein interaction and surface expression assays with tissue-specific analysis","pmids":["21814048","20134095"],"confidence":"Medium","gaps":["Stoichiometry and structural basis of the heterodimer not resolved at this stage","Whether catalytic activity contributes to transport unclear"]},{"year":2019,"claim":"Placed ACE2 within central blood-pressure control, showing PVN GABAergic neuronal ACE2 sustains inhibitory tone to presympathetic neurons and restrains hypertension, with ADAM17 shedding opposing this.","evidence":"Conditional neuron-specific knockout mice, neuron cultures, photoactivation, BP telemetry, pharmacological blockade","pmids":["31564162"],"confidence":"High","gaps":["Local peptide signaling (Ang-(1-7)/Mas) linking ACE2 to GABA tone not directly traced","Which downstream effectors set GABAergic strength unresolved"]},{"year":2019,"claim":"Revealed an anti-angiogenic, anti-metastatic role for ACE2 in breast cancer via suppression of VEGFa/VEGFR2-MEK-ERK signaling, extending ACE2 function beyond cardiovascular and viral contexts.","evidence":"Migration and tube-formation assays, pathway Western blotting, zebrafish xenograft","pmids":["31023337"],"confidence":"Medium","gaps":["Whether the effect requires enzymatic activity or Ang-(1-7)/Mas signaling untested","Single zebrafish in vivo model"]},{"year":2020,"claim":"Localized ACE2 protein to airway motile cilia of upper and lower respiratory epithelium, identifying the initial subcellular site of SARS-CoV-2 entry and showing ACE inhibitors/ARBs do not raise ciliary ACE2.","evidence":"Immunofluorescence, multiplex imaging, and IHC across a diverse human tissue panel","pmids":["33116139"],"confidence":"High","gaps":["Mechanism targeting ACE2 to the ciliary membrane not defined","Functional contribution of ciliary localization to enzymatic role unaddressed"]},{"year":2020,"claim":"Identified epigenetic repression of ACE2, with EZH2-mediated H3K27me3 silencing the promoter and EZH2 loss de-repressing ACE2, establishing a chromatin-level control of receptor/enzyme abundance.","evidence":"EZH2 knockout in hESCs with RNA-seq and ChIP-seq","pmids":["32291076"],"confidence":"Medium","gaps":["Physiological signals modulating EZH2 occupancy at ACE2 unknown","Relevance in differentiated airway/intestinal cells not shown"]},{"year":2020,"claim":"Showed ACE2-B0AT1/SIT1 heterodimers assemble quaternary structures that present spike-binding surfaces, integrating the amino-acid-transport partnership with coronavirus recognition.","evidence":"Co-IP, structural studies, viral binding assays","pmids":["33140827"],"confidence":"Medium","gaps":["Whether transporter association modulates infection in vivo untested","Single-lab structural interpretation"]},{"year":2021,"claim":"Defined post-translational control of ACE2 surface residence: direct binding of the ACE2 C-terminal PDZ motif to both NHERF1 PDZ domains tethers ACE2 at the membrane and tunes viral entry.","evidence":"Co-IP, proximity ligation in human lung/intestine cells, PDZ-motif mutagenesis, pseudovirus entry assays","pmids":["34189428"],"confidence":"High","gaps":["How NHERF1 binding is dynamically regulated by physiological signals unknown","Interplay between NHERF1 tethering and Nedd4-2 degradation not jointly resolved"]},{"year":2021,"claim":"Showed post-infection ACE2 autoantibodies functionally inhibit ACE2 enzymatic activity, providing an acquired-immunity route to suppress the protective ACE2 axis.","evidence":"ELISA for ACE2 antibodies and in vitro plasma inhibition assays","pmids":["34478478"],"confidence":"Medium","gaps":["Epitope and mechanism of catalytic inhibition undefined","In vivo physiological consequence not established"]},{"year":2022,"claim":"Connected ACE2 to whole-body energy balance, demonstrating the ACE2/Ang-(1-7)/Mas1 axis drives brown-fat thermogenesis through Akt/FoxO1 and PKA pathways inducing UCP1.","evidence":"Ace2 and Mas1 knockout mice, BAT transplantation, Ace2 overexpression, Ang-(1-7) infusion, pathway Western blotting","pmids":["35014608"],"confidence":"High","gaps":["How cold stimulus induces ACE2 in BAT not mechanistically traced","Relative contribution of local vs. systemic Ang-(1-7) unresolved"]},{"year":2022,"claim":"Demonstrated an intestinal ACE2 gut-eye axis, where intestinal ACE2/MasR signaling via GSK-3β/c-Myc preserves barrier integrity and delays diabetic retinopathy.","evidence":"Intestinal ACE2 overexpression and ACE2-probiotic delivery in Akita mice, pathway analysis, permeability and retinal imaging","pmids":["36448480"],"confidence":"High","gaps":["Mediators linking gut barrier to retinal protection not fully defined","Whether glucose-transporter downregulation is the sole effector unclear"]},{"year":2022,"claim":"Mechanistically dissected SARS-CoV-2-induced ACE2 down-regulation, showing clathrin/AP2-dependent endocytosis and lysosomal degradation drive loss of ACE2 and pathogenic cytokine signaling, blockable by soluble ACE2.","evidence":"In vivo infection model, cell culture, siRNA knockdown, gene-expression profiling, endocytosis inhibitor studies","pmids":["36287912"],"confidence":"High","gaps":["Adaptor coupling spike binding to AP2 recruitment not pinpointed","Contribution of lost enzymatic vs. transporter function to disease not separated"]},{"year":2023,"claim":"Identified Nedd4-2 as the E3 ligase ubiquitinating ACE2 C-terminal lysines during Ang II hypertension; a ubiquitination-resistant ACE2-5R mutant resists degradation and lowers blood pressure when expressed in the BNST, defining a feedback loop coupling Ang II to ACE2 turnover.","evidence":"Proteomics, in vitro gain/loss-of-function, site-directed mutagenesis, optogenetics, BP telemetry","pmids":["37161607"],"confidence":"High","gaps":["Signaling that activates Nedd4-2 toward ACE2 upon Ang II not fully traced","Interaction with NHERF1 tethering in setting turnover not co-analyzed"]},{"year":2023,"claim":"Revealed reciprocal ACE2-EGFR cross-talk in which ACE2 binds EGFR and spike-driven EGFR-MAPK activation regulates ACE2 abundance and supports infection, linking ACE2 to growth-factor signaling.","evidence":"Co-IP/proximity assays, EGFR inhibition, pseudotyped and authentic SARS-CoV-2 infection, Western blotting","pmids":["37402592"],"confidence":"Medium","gaps":["Direct vs. indirect nature of the ACE2-EGFR interaction not fully resolved","Single-lab study"]},{"year":null,"claim":"How the multiple layers controlling ACE2 abundance — NHERF1 tethering, Nedd4-2 ubiquitination, EZH2 repression, endocytic degradation, and EGFR cross-talk — are integrated to set tissue-specific ACE2 levels during physiology and infection remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model coordinating transcriptional, trafficking, and degradative control","Quantitative contribution of each layer in different tissues unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,17,18]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,18]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[1,2,8]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[1,8]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[9,3,5]},{"term_id":"GO:0005929","term_label":"cilium","supporting_discovery_ids":[4]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[6,11,14]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[8,18]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[11,14]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[10]}],"complexes":["ACE2-B0AT1 (SLC6A19) heterodimer","ACE2-SIT1 (SLC6A20) heterodimer"],"partners":["SLC6A19","SLC6A20","NHERF1","NEDD4L","EGFR","TMEM27"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9BYF1","full_name":"Angiotensin-converting enzyme 2","aliases":["Angiotensin-converting enzyme homolog","ACEH","Angiotensin-converting enzyme-related carboxypeptidase","ACE-related carboxypeptidase","Metalloprotease MPROT15"],"length_aa":805,"mass_kda":92.5,"function":"Essential counter-regulatory carboxypeptidase of the renin-angiotensin hormone system that is a critical regulator of blood volume, systemic vascular resistance, and thus cardiovascular homeostasis (PubMed:27217402). Converts angiotensin I to angiotensin 1-9, a nine-amino acid peptide with anti-hypertrophic effects in cardiomyocytes, and angiotensin II to angiotensin 1-7, which then acts as a beneficial vasodilator and anti-proliferation agent, counterbalancing the actions of the vasoconstrictor angiotensin II (PubMed:10924499, PubMed:10969042, PubMed:11815627, PubMed:14504186, PubMed:19021774). Also removes the C-terminal residue from three other vasoactive peptides, neurotensin, kinetensin, and des-Arg bradykinin, but is not active on bradykinin (PubMed:10969042, PubMed:11815627). Also cleaves other biological peptides, such as apelins (apelin-13, [Pyr1]apelin-13, apelin-17, apelin-36), casomorphins (beta-casomorphin-7, neocasomorphin) and dynorphin A with high efficiency (PubMed:11815627, PubMed:27217402, PubMed:28293165). In addition, ACE2 C-terminus is homologous to collectrin and is responsible for the trafficking of the neutral amino acid transporter SL6A19 to the plasma membrane of gut epithelial cells via direct interaction, regulating its expression on the cell surface and its catalytic activity (PubMed:18424768, PubMed:19185582) (Microbial infection) Acts as a receptor for human coronaviruses SARS-CoV and SARS-CoV-2, as well as human coronavirus NL63/HCoV-NL63 Non-functional as a carboxypeptidase (Microbial infection) Non-functional as a receptor for human coronavirus SARS-CoV-2","subcellular_location":"Apical cell membrane","url":"https://www.uniprot.org/uniprotkb/Q9BYF1/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ACE2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ACE2","total_profiled":1310},"omim":[{"mim_id":"620564","title":"ANTAGONIST OF MITOTIC EXIT NETWORK 1 HOMOLOG; AMN1","url":"https://www.omim.org/entry/620564"},{"mim_id":"613413","title":"TRANSMEMBRANE PROTEIN 106B; TMEM106B","url":"https://www.omim.org/entry/613413"},{"mim_id":"608893","title":"SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER TRANSPORTER), MEMBER 19; SLC6A19","url":"https://www.omim.org/entry/608893"},{"mim_id":"605872","title":"C-TYPE LECTIN DOMAIN FAMILY 4, MEMBER M; CLEC4M","url":"https://www.omim.org/entry/605872"},{"mim_id":"602060","title":"TRANSMEMBRANE SERINE PROTEASE 2; TMPRSS2","url":"https://www.omim.org/entry/602060"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"gallbladder","ntpm":62.3},{"tissue":"intestine","ntpm":230.5},{"tissue":"kidney","ntpm":82.4}],"url":"https://www.proteinatlas.org/search/ACE2"},"hgnc":{"alias_symbol":["ACEH"],"prev_symbol":[]},"alphafold":{"accession":"Q9BYF1","domains":[{"cath_id":"-","chopping":"296-396","consensus_level":"medium","plddt":95.48,"start":296,"end":396},{"cath_id":"-","chopping":"615-726","consensus_level":"high","plddt":93.6729,"start":615,"end":726}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BYF1","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BYF1-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BYF1-F1-predicted_aligned_error_v6.png","plddt_mean":90.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ACE2","jax_strain_url":"https://www.jax.org/strain/search?query=ACE2"},"sequence":{"accession":"Q9BYF1","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9BYF1.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9BYF1/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BYF1"}},"corpus_meta":[{"pmid":"32660650","id":"PMC_32660650","title":"Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19.","date":"2020","source":"Critical care (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/32660650","citation_count":757,"is_preprint":false},{"pmid":"33389262","id":"PMC_33389262","title":"COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection.","date":"2021","source":"European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/33389262","citation_count":564,"is_preprint":false},{"pmid":"32228252","id":"PMC_32228252","title":"COVID-19, ACE2, and the cardiovascular consequences.","date":"2020","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32228252","citation_count":525,"is_preprint":false},{"pmid":"15671045","id":"PMC_15671045","title":"Myocardial infarction increases ACE2 expression in rat and humans.","date":"2005","source":"European heart journal","url":"https://pubmed.ncbi.nlm.nih.gov/15671045","citation_count":346,"is_preprint":false},{"pmid":"17464936","id":"PMC_17464936","title":"The emerging role of ACE2 in physiology and disease.","date":"2007","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17464936","citation_count":339,"is_preprint":false},{"pmid":"32582574","id":"PMC_32582574","title":"ACE2, Much More Than Just a Receptor for SARS-COV-2.","date":"2020","source":"Frontiers in cellular and infection microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/32582574","citation_count":268,"is_preprint":false},{"pmid":"27082314","id":"PMC_27082314","title":"Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease.","date":"2016","source":"Shock (Augusta, Ga.)","url":"https://pubmed.ncbi.nlm.nih.gov/27082314","citation_count":230,"is_preprint":false},{"pmid":"31023337","id":"PMC_31023337","title":"ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/31023337","citation_count":224,"is_preprint":false},{"pmid":"17049503","id":"PMC_17049503","title":"ACE2 of the heart: From angiotensin I to angiotensin (1-7).","date":"2006","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/17049503","citation_count":196,"is_preprint":false},{"pmid":"33116139","id":"PMC_33116139","title":"ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33116139","citation_count":194,"is_preprint":false},{"pmid":"34782609","id":"PMC_34782609","title":"The glycosylation in SARS-CoV-2 and its receptor ACE2.","date":"2021","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34782609","citation_count":179,"is_preprint":false},{"pmid":"35114688","id":"PMC_35114688","title":"ACE2 binding is an ancestral and evolvable trait of sarbecoviruses.","date":"2022","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/35114688","citation_count":174,"is_preprint":false},{"pmid":"32882331","id":"PMC_32882331","title":"Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome.","date":"2020","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/32882331","citation_count":157,"is_preprint":false},{"pmid":"34478478","id":"PMC_34478478","title":"Development of ACE2 autoantibodies after SARS-CoV-2 infection.","date":"2021","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/34478478","citation_count":153,"is_preprint":false},{"pmid":"20134095","id":"PMC_20134095","title":"Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis.","date":"2010","source":"Circulation journal : official journal of the Japanese Circulation Society","url":"https://pubmed.ncbi.nlm.nih.gov/20134095","citation_count":150,"is_preprint":false},{"pmid":"25664248","id":"PMC_25664248","title":"ACE and ACE2 in kidney disease.","date":"2015","source":"World journal of nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/25664248","citation_count":144,"is_preprint":false},{"pmid":"36477529","id":"PMC_36477529","title":"Close relatives of MERS-CoV in bats use ACE2 as their functional receptors.","date":"2022","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/36477529","citation_count":139,"is_preprint":false},{"pmid":"12025971","id":"PMC_12025971","title":"ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors.","date":"2002","source":"Canadian journal of physiology and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12025971","citation_count":132,"is_preprint":false},{"pmid":"21045683","id":"PMC_21045683","title":"ACE2: more of Ang-(1-7) or less Ang II?","date":"2011","source":"Current opinion in nephrology and hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/21045683","citation_count":131,"is_preprint":false},{"pmid":"33110195","id":"PMC_33110195","title":"Comparative ACE2 variation and primate COVID-19 risk.","date":"2020","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/33110195","citation_count":130,"is_preprint":false},{"pmid":"32364961","id":"PMC_32364961","title":"Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter?","date":"2020","source":"Respiratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32364961","citation_count":127,"is_preprint":false},{"pmid":"25019157","id":"PMC_25019157","title":"ACE and ACE2 in inflammation: a tale of two enzymes.","date":"2014","source":"Inflammation & allergy drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/25019157","citation_count":122,"is_preprint":false},{"pmid":"18945956","id":"PMC_18945956","title":"ACE2 expression and activity are enhanced during pregnancy.","date":"2008","source":"American journal of physiology. Regulatory, integrative and comparative physiology","url":"https://pubmed.ncbi.nlm.nih.gov/18945956","citation_count":116,"is_preprint":false},{"pmid":"32665962","id":"PMC_32665962","title":"The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19.","date":"2020","source":"Molecular therapy. Methods & clinical development","url":"https://pubmed.ncbi.nlm.nih.gov/32665962","citation_count":107,"is_preprint":false},{"pmid":"33072500","id":"PMC_33072500","title":"Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator.","date":"2020","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/33072500","citation_count":102,"is_preprint":false},{"pmid":"32374427","id":"PMC_32374427","title":"Expression of the COVID-19 receptor ACE2 in the human conjunctiva.","date":"2020","source":"Journal of medical virology","url":"https://pubmed.ncbi.nlm.nih.gov/32374427","citation_count":101,"is_preprint":false},{"pmid":"32522846","id":"PMC_32522846","title":"ACE2 and COVID-19 and the resulting ARDS.","date":"2020","source":"Postgraduate medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/32522846","citation_count":93,"is_preprint":false},{"pmid":"34194422","id":"PMC_34194422","title":"Expression of ACE2, Soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin-(1-7) Is Modulated in COVID-19 Patients.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34194422","citation_count":88,"is_preprint":false},{"pmid":"32780149","id":"PMC_32780149","title":"Advances in research on ACE2 as a receptor for 2019-nCoV.","date":"2020","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/32780149","citation_count":84,"is_preprint":false},{"pmid":"33140827","id":"PMC_33140827","title":"ACE2 and gut amino acid transport.","date":"2020","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/33140827","citation_count":81,"is_preprint":false},{"pmid":"28413960","id":"PMC_28413960","title":"Circulating ACE2 in Cardiovascular and Kidney Diseases.","date":"2017","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28413960","citation_count":81,"is_preprint":false},{"pmid":"26322922","id":"PMC_26322922","title":"ACE2 and Microbiota: Emerging Targets for Cardiopulmonary Disease Therapy.","date":"2015","source":"Journal of cardiovascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26322922","citation_count":79,"is_preprint":false},{"pmid":"33380340","id":"PMC_33380340","title":"ACE2: the molecular doorway to SARS-CoV-2.","date":"2020","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/33380340","citation_count":78,"is_preprint":false},{"pmid":"33607284","id":"PMC_33607284","title":"Variants in ACE2; potential influences on virus infection and COVID-19 severity.","date":"2021","source":"Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/33607284","citation_count":77,"is_preprint":false},{"pmid":"31564162","id":"PMC_31564162","title":"ACE2 and ADAM17 Interaction Regulates the Activity of Presympathetic Neurons.","date":"2019","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/31564162","citation_count":76,"is_preprint":false},{"pmid":"25815211","id":"PMC_25815211","title":"The ACE2/Apelin Signaling, MicroRNAs, and Hypertension.","date":"2015","source":"International journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/25815211","citation_count":75,"is_preprint":false},{"pmid":"24329564","id":"PMC_24329564","title":"Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications.","date":"2014","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/24329564","citation_count":72,"is_preprint":false},{"pmid":"33592054","id":"PMC_33592054","title":"Angiotensin-converting enzyme 2 (ACE2) expression increases with age in patients requiring mechanical ventilation.","date":"2021","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/33592054","citation_count":70,"is_preprint":false},{"pmid":"23013041","id":"PMC_23013041","title":"The ACE2 gene: its potential as a functional candidate for cardiovascular disease.","date":"2013","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/23013041","citation_count":69,"is_preprint":false},{"pmid":"15947194","id":"PMC_15947194","title":"ACE2, CBK1, and BUD4 in budding and cell separation.","date":"2005","source":"Eukaryotic cell","url":"https://pubmed.ncbi.nlm.nih.gov/15947194","citation_count":65,"is_preprint":false},{"pmid":"32956843","id":"PMC_32956843","title":"Angiotensin-converting enzyme 2 (ACE2): COVID 19 gate way to multiple organ failure syndromes.","date":"2020","source":"Respiratory physiology & neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/32956843","citation_count":65,"is_preprint":false},{"pmid":"35096642","id":"PMC_35096642","title":"ACE2 Shedding and the Role in COVID-19.","date":"2022","source":"Frontiers in cellular and infection microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/35096642","citation_count":63,"is_preprint":false},{"pmid":"32745604","id":"PMC_32745604","title":"Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting.","date":"2020","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32745604","citation_count":63,"is_preprint":false},{"pmid":"36287912","id":"PMC_36287912","title":"SARS-CoV-2 down-regulates ACE2 through lysosomal degradation.","date":"2022","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/36287912","citation_count":59,"is_preprint":false},{"pmid":"18775121","id":"PMC_18775121","title":"Pharmacologic modulation of ACE2 expression.","date":"2008","source":"Current hypertension reports","url":"https://pubmed.ncbi.nlm.nih.gov/18775121","citation_count":59,"is_preprint":false},{"pmid":"33443121","id":"PMC_33443121","title":"Manipulation of ACE2 expression in COVID-19.","date":"2020","source":"Open heart","url":"https://pubmed.ncbi.nlm.nih.gov/33443121","citation_count":55,"is_preprint":false},{"pmid":"32291076","id":"PMC_32291076","title":"EZH2-mediated H3K27me3 inhibits ACE2 expression.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/32291076","citation_count":53,"is_preprint":false},{"pmid":"21814048","id":"PMC_21814048","title":"Collectrin and ACE2 in renal and intestinal amino acid transport.","date":"2011","source":"Channels (Austin, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/21814048","citation_count":52,"is_preprint":false},{"pmid":"33101066","id":"PMC_33101066","title":"Angiotensin Converting Enzyme 2 (ACE2) in Pregnancy: Preeclampsia and Small for Gestational Age.","date":"2020","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33101066","citation_count":52,"is_preprint":false},{"pmid":"35003058","id":"PMC_35003058","title":"Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35003058","citation_count":51,"is_preprint":false},{"pmid":"32818905","id":"PMC_32818905","title":"ACE2, Metformin, and COVID-19.","date":"2020","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/32818905","citation_count":49,"is_preprint":false},{"pmid":"33057007","id":"PMC_33057007","title":"ACE2 mouse models: a toolbox for cardiovascular and pulmonary research.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33057007","citation_count":49,"is_preprint":false},{"pmid":"32816230","id":"PMC_32816230","title":"ACE2 & TMPRSS2 Expressions in Head & Neck Tissues: A Systematic Review.","date":"2020","source":"Head and neck pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32816230","citation_count":48,"is_preprint":false},{"pmid":"22048948","id":"PMC_22048948","title":"Characterization and significance of ACE2 and Mas receptor in human colon adenocarcinoma.","date":"2011","source":"Journal of the renin-angiotensin-aldosterone system : JRAAS","url":"https://pubmed.ncbi.nlm.nih.gov/22048948","citation_count":48,"is_preprint":false},{"pmid":"36759512","id":"PMC_36759512","title":"Unique DUOX2+ACE2+ small cholangiocytes are pathogenic targets for primary biliary cholangitis.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36759512","citation_count":47,"is_preprint":false},{"pmid":"33264412","id":"PMC_33264412","title":"ACE2 in the renin-angiotensin system.","date":"2020","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/33264412","citation_count":47,"is_preprint":false},{"pmid":"33284956","id":"PMC_33284956","title":"ACE2: from protection of liver disease to propagation of COVID-19.","date":"2020","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/33284956","citation_count":42,"is_preprint":false},{"pmid":"39922192","id":"PMC_39922192","title":"Molecular basis of convergent evolution of ACE2 receptor utilization among HKU5 coronaviruses.","date":"2025","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/39922192","citation_count":41,"is_preprint":false},{"pmid":"39922191","id":"PMC_39922191","title":"Multiple independent acquisitions of ACE2 usage in MERS-related coronaviruses.","date":"2025","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/39922191","citation_count":40,"is_preprint":false},{"pmid":"33833750","id":"PMC_33833750","title":"COVID-19-A Theory of Autoimmunity Against ACE-2 Explained.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33833750","citation_count":38,"is_preprint":false},{"pmid":"32974030","id":"PMC_32974030","title":"Lions, tigers and kittens too: ACE2 and susceptibility to COVID-19.","date":"2020","source":"Evolution, medicine, and public health","url":"https://pubmed.ncbi.nlm.nih.gov/32974030","citation_count":36,"is_preprint":false},{"pmid":"36448480","id":"PMC_36448480","title":"Maintenance of Enteral ACE2 Prevents Diabetic Retinopathy in Type 1 Diabetes.","date":"2022","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/36448480","citation_count":35,"is_preprint":false},{"pmid":"35151768","id":"PMC_35151768","title":"Angiotensin-converting enzyme 2 (ACE2): Two decades of revelations and re-evaluation.","date":"2022","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/35151768","citation_count":35,"is_preprint":false},{"pmid":"35387486","id":"PMC_35387486","title":"Genetic Landscape of the ACE2 Coronavirus Receptor.","date":"2022","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/35387486","citation_count":35,"is_preprint":false},{"pmid":"35902282","id":"PMC_35902282","title":"Engineering ACE2 decoy receptors to combat viral escapability.","date":"2022","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35902282","citation_count":34,"is_preprint":false},{"pmid":"33725024","id":"PMC_33725024","title":"Variability in digestive and respiratory tract Ace2 expression is associated with the microbiome.","date":"2021","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/33725024","citation_count":34,"is_preprint":false},{"pmid":"32663362","id":"PMC_32663362","title":"ACE2, the Receptor that Enables Infection by SARS-CoV-2: Biochemistry, Structure, Allostery and Evaluation of the Potential Development of ACE2 Modulators.","date":"2020","source":"ChemMedChem","url":"https://pubmed.ncbi.nlm.nih.gov/32663362","citation_count":34,"is_preprint":false},{"pmid":"39889696","id":"PMC_39889696","title":"Early fusion intermediate of ACE2-using coronavirus spike acting as an antiviral target.","date":"2025","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/39889696","citation_count":33,"is_preprint":false},{"pmid":"32469114","id":"PMC_32469114","title":"An update on ACE2 amplification and its therapeutic potential.","date":"2020","source":"Acta physiologica (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/32469114","citation_count":33,"is_preprint":false},{"pmid":"33125431","id":"PMC_33125431","title":"Kidney ACE2 expression: Implications for chronic kidney disease.","date":"2020","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/33125431","citation_count":32,"is_preprint":false},{"pmid":"34402717","id":"PMC_34402717","title":"Resveratrol supplementation reduces ACE2 expression in human adipose tissue.","date":"2021","source":"Adipocyte","url":"https://pubmed.ncbi.nlm.nih.gov/34402717","citation_count":32,"is_preprint":false},{"pmid":"35371596","id":"PMC_35371596","title":"ACE2 and COVID-19 Susceptibility and Severity.","date":"2022","source":"Aging and disease","url":"https://pubmed.ncbi.nlm.nih.gov/35371596","citation_count":31,"is_preprint":false},{"pmid":"32901821","id":"PMC_32901821","title":"Interaction between the apelinergic system and ACE2 in the cardiovascular system: therapeutic implications.","date":"2020","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/32901821","citation_count":31,"is_preprint":false},{"pmid":"34590312","id":"PMC_34590312","title":"ACE2 and TMPRSS2 in human saliva can adsorb to the oral mucosal epithelium.","date":"2021","source":"Journal of anatomy","url":"https://pubmed.ncbi.nlm.nih.gov/34590312","citation_count":31,"is_preprint":false},{"pmid":"34305426","id":"PMC_34305426","title":"RAAS, ACE2 and COVID-19; a mechanistic review.","date":"2021","source":"Saudi journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34305426","citation_count":29,"is_preprint":false},{"pmid":"38624559","id":"PMC_38624559","title":"COVID-19 susceptibility: potential of ACE2 polymorphisms.","date":"2020","source":"The Egyptian journal of medical human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38624559","citation_count":29,"is_preprint":false},{"pmid":"37161607","id":"PMC_37161607","title":"Nedd4-2 up-regulation is associated with ACE2 ubiquitination in hypertension.","date":"2023","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/37161607","citation_count":29,"is_preprint":false},{"pmid":"21346373","id":"PMC_21346373","title":"Expression of ACE and ACE2 in patients with hypertensive nephrosclerosis.","date":"2011","source":"Kidney & blood pressure research","url":"https://pubmed.ncbi.nlm.nih.gov/21346373","citation_count":29,"is_preprint":false},{"pmid":"35014608","id":"PMC_35014608","title":"ACE2 pathway regulates thermogenesis and energy metabolism.","date":"2022","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/35014608","citation_count":28,"is_preprint":false},{"pmid":"33083800","id":"PMC_33083800","title":"Sex, androgens and regulation of pulmonary AR, TMPRSS2 and ACE2.","date":"2020","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/33083800","citation_count":27,"is_preprint":false},{"pmid":"34668773","id":"PMC_34668773","title":"Susceptibilities of Human ACE2 Genetic Variants in Coronavirus Infection.","date":"2021","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/34668773","citation_count":27,"is_preprint":false},{"pmid":"32759311","id":"PMC_32759311","title":"Molecules in pathogenesis: angiotensin converting enzyme 2 (ACE2).","date":"2020","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32759311","citation_count":26,"is_preprint":false},{"pmid":"33973262","id":"PMC_33973262","title":"ACE2-based decoy receptors for SARS coronavirus 2.","date":"2021","source":"Proteins","url":"https://pubmed.ncbi.nlm.nih.gov/33973262","citation_count":25,"is_preprint":false},{"pmid":"35739259","id":"PMC_35739259","title":"Effect of age on human ACE2 and ACE2-expressing alveolar type II cells levels.","date":"2022","source":"Pediatric research","url":"https://pubmed.ncbi.nlm.nih.gov/35739259","citation_count":25,"is_preprint":false},{"pmid":"18679036","id":"PMC_18679036","title":"Renal ACE and ACE2 expression in early diabetic rats.","date":"2008","source":"Nephron. Experimental nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/18679036","citation_count":25,"is_preprint":false},{"pmid":"37402592","id":"PMC_37402592","title":"ACE2-EGFR-MAPK signaling contributes to SARS-CoV-2 infection.","date":"2023","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/37402592","citation_count":24,"is_preprint":false},{"pmid":"33723522","id":"PMC_33723522","title":"ACE2: At the crossroad of COVID-19 and lung cancer.","date":"2021","source":"Gene reports","url":"https://pubmed.ncbi.nlm.nih.gov/33723522","citation_count":24,"is_preprint":false},{"pmid":"36851081","id":"PMC_36851081","title":"S Protein, ACE2 and Host Cell Proteases in SARS-CoV-2 Cell Entry and Infectivity; Is Soluble ACE2 a Two Blade Sword? A Narrative Review.","date":"2023","source":"Vaccines","url":"https://pubmed.ncbi.nlm.nih.gov/36851081","citation_count":24,"is_preprint":false},{"pmid":"28758592","id":"PMC_28758592","title":"The Angiotensin Converting Enzyme 2 (ACE2), Gut Microbiota, and Cardiovascular Health.","date":"2017","source":"Protein and peptide letters","url":"https://pubmed.ncbi.nlm.nih.gov/28758592","citation_count":23,"is_preprint":false},{"pmid":"37784209","id":"PMC_37784209","title":"Higher angiotensin-converting enzyme 2 (ACE2) levels in the brain of individuals with Alzheimer's disease.","date":"2023","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/37784209","citation_count":22,"is_preprint":false},{"pmid":"40306315","id":"PMC_40306315","title":"A MERS-CoV-like mink coronavirus uses ACE2 as an entry receptor.","date":"2025","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/40306315","citation_count":21,"is_preprint":false},{"pmid":"40436893","id":"PMC_40436893","title":"ACE2 from Pipistrellus abramus bats is a receptor for HKU5 coronaviruses.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40436893","citation_count":21,"is_preprint":false},{"pmid":"34012391","id":"PMC_34012391","title":"Natural Products Modulating Angiotensin Converting Enzyme 2 (ACE2) as Potential COVID-19 Therapies.","date":"2021","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34012391","citation_count":21,"is_preprint":false},{"pmid":"35451691","id":"PMC_35451691","title":"ACE2, Circumventricular Organs and the Hypothalamus, and COVID-19.","date":"2022","source":"Neuromolecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35451691","citation_count":20,"is_preprint":false},{"pmid":"35368365","id":"PMC_35368365","title":"Expression of ACE2 in the Intact and Acutely Injured Kidney.","date":"2021","source":"Kidney360","url":"https://pubmed.ncbi.nlm.nih.gov/35368365","citation_count":20,"is_preprint":false},{"pmid":"33838329","id":"PMC_33838329","title":"E-cigarette vape and lung ACE2 expression: Implications for coronavirus vulnerability.","date":"2021","source":"Environmental toxicology and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33838329","citation_count":20,"is_preprint":false},{"pmid":"33196086","id":"PMC_33196086","title":"Angiotensin-converting enzyme 2 (ACE2), angiotensin-(1-7) and Mas receptor in gonadal and reproductive functions.","date":"2020","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/33196086","citation_count":20,"is_preprint":false},{"pmid":"34189428","id":"PMC_34189428","title":"ACE2 interaction with cytoplasmic PDZ protein enhances SARS-CoV-2 invasion.","date":"2021","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/34189428","citation_count":20,"is_preprint":false},{"pmid":"35000261","id":"PMC_35000261","title":"ACE2 and TMPRSS2 immunolocalization and oral manifestations of COVID-19.","date":"2022","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/35000261","citation_count":19,"is_preprint":false},{"pmid":"33203793","id":"PMC_33203793","title":"Cell differentiation and aging accompanied by depletion of the ACE2 protein.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/33203793","citation_count":19,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47779,"output_tokens":5316,"usd":0.111538,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13824,"output_tokens":5616,"usd":0.10476,"stage2_stop_reason":"end_turn"},"total_usd":0.216298,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"ACE2 (ACEH) is a zinc metallocarboxypeptidase containing an N-terminal signal sequence, a single catalytic domain with zinc-binding motif (HEMGH), a transmembrane region, and a small C-terminal cytosolic domain. It functions as a carboxypeptidase on angiotensin I (cleaving to Ang 1-9) and angiotensin II (cleaving to Ang 1-7), does not hydrolyse bradykinin, and is insensitive to ACE inhibitors. The protein is proposed to have evolved as a chimera of a single ACE-like catalytic domain and a collectrin-like C-terminal domain.\",\n      \"method\": \"Cloning, functional expression, in vitro enzymatic assays, domain analysis\",\n      \"journal\": \"Canadian journal of physiology and pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro enzymatic reconstitution with substrate characterization and domain mutagenesis context, foundational characterization paper replicated across multiple subsequent studies\",\n      \"pmids\": [\"12025971\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ACE2 3D crystal structure was determined, and the enzyme was shown to cleave angiotensin II to angiotensin-(1-7) and to serve as a receptor for SARS and NL63 coronaviruses. ACE2 protein structure and function were validated through knockout and knock-in mouse models.\",\n      \"method\": \"Crystal structure determination, knockout/knock-in mouse models, enzymatic activity assays\",\n      \"journal\": \"The Journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — 3D structure determination combined with genetic models and enzymatic assays, independently replicated\",\n      \"pmids\": [\"17464936\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ACE2 functions as a key SARS-coronavirus receptor and plays a protective role in SARS pathogenesis. ACE2 also functions as an amino acid transporter (homologous to collectrin), explaining the pathogenic role of ACE2 mutations in Hartnup disorder.\",\n      \"method\": \"Genetic models (ACE2 knockout mice), collectrin homology analysis, amino acid transport assays\",\n      \"journal\": \"Circulation journal : official journal of the Japanese Circulation Society\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function models with defined phenotypic readouts, single review summarizing multiple experimental studies\",\n      \"pmids\": [\"20134095\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ACE2 heterodimerizes with the neutral amino acid transporter B0AT1 (SLC6A19) in the small intestine, and this association is required for surface expression of B0AT1. In the kidney, ACE2 associates with B0AT3 through its homolog collectrin (Tmem27) in a tissue-specific manner.\",\n      \"method\": \"Protein interaction studies, surface expression assays, tissue-specific expression analysis\",\n      \"journal\": \"Channels (Austin, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical interaction studies with functional consequence (surface expression), single review consolidating experimental findings\",\n      \"pmids\": [\"21814048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ACE2 protein robustly localizes within the motile cilia of airway epithelial cells in the upper (nasal) and lower (pulmonary) respiratory tract, representing the initial subcellular site of SARS-CoV-2 viral entry. ACE inhibitors or ARBs do not increase ciliary ACE2 expression.\",\n      \"method\": \"Immunofluorescence, multiplex imaging of banked human tissue, immunohistochemistry across diverse donor panel\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct localization experiment with functional consequence (viral entry site), multiple orthogonal methods, diverse human tissue panel\",\n      \"pmids\": [\"33116139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ACE2 protein heterodimerizes with B0AT1 (SLC6A19) or SIT1 (SLC6A20) in the small intestine, and these heterodimers can form quaternary structures that serve as binding sites for SARS-CoV-2 spike glycoproteins. ACE2-B0AT1 association is required for surface expression of the transporter and may favor substrate amino acid supply to B0AT1.\",\n      \"method\": \"Co-immunoprecipitation, structural studies, viral binding assays\",\n      \"journal\": \"Clinical science (London, England : 1979)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical heterodimerization with functional consequence for transporter surface expression, single lab review\",\n      \"pmids\": [\"33140827\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ACE2 is expressed on GABAergic neurons in the hypothalamic paraventricular nucleus (PVN), where it supports inhibitory GABAergic tone to presympathetic neurons. ACE2 deletion from all neurons reduces inhibitory inputs to presympathetic neurons and increases blood pressure. ADAM17 co-localizes with AT1 receptors on Sim1 neurons and its knockdown prevents acute pressor response to centrally administered angiotensin-II and preserves ACE2 activity during salt-sensitive hypertension.\",\n      \"method\": \"Conditional neuron-specific knockout mice, primary neuron cultures, photoactivation, blood pressure telemetry, bicuculline pharmacological blockade\",\n      \"journal\": \"Hypertension (Dallas, Tex. : 1979)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional knockout mouse models with multiple orthogonal methods (cultures, telemetry, pharmacology, optogenetics), direct mechanistic pathway placement\",\n      \"pmids\": [\"31564162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"EZH2-mediated H3K27me3 at the ACE2 promoter region inhibits ACE2 expression. EZH2 knockout in human embryonic stem cells significantly increases ACE2 expression, confirmed by ChIP-seq showing decreased H3K27me3 and increased H3K27ac signals at the ACE2 promoter.\",\n      \"method\": \"EZH2 knockout in hESCs, RNA-seq, ChIP-seq, Western blotting\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with ChIP-seq validation of epigenetic marks, single lab with two orthogonal methods\",\n      \"pmids\": [\"32291076\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SARS-CoV-2 infection down-regulates ACE2 by inducing clathrin- and AP2-dependent endocytosis, leading to lysosomal degradation of ACE2. ACE2 knockdown mimics the downstream gene expression pattern of SARS-CoV-2 S-treated cells (activated cytokine signaling associated with respiratory distress). A soluble ACE2 fragment can block this down-regulation and viral infection.\",\n      \"method\": \"In vivo animal infection model, in vitro cell culture, siRNA knockdown, gene expression profiling, inhibitor studies\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo and in vitro models with mechanistic dissection of endocytic pathway, multiple orthogonal methods\",\n      \"pmids\": [\"36287912\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ACE2 directly binds both PDZ domains of the scaffolding protein NHERF1 via its intracellular C-terminal PDZ-recognition motif. This interaction tethers ACE2 at the membrane, increasing ACE2 membrane residence; disruption of either NHERF1 PDZ core-binding motif or the ACE2 PDZ recognition sequence eliminates binding. Loss of this interaction decreases ACE2 membrane residence and reduces pseudotyped SARS-CoV-2 entry, while ablating NHERF1 interaction accelerated entry, revealing a regulatory role.\",\n      \"method\": \"Co-immunoprecipitation, proximity ligation assays in human lung and intestine cells, mutagenesis of PDZ motifs, pseudovirus entry assays\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct binding demonstrated by Co-IP and proximity ligation, mutagenesis of interaction motifs, functional consequence measured by viral entry assay, multiple orthogonal methods\",\n      \"pmids\": [\"34189428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Nedd4-2 is an E3 ubiquitin ligase that ubiquitinates ACE2, leading to its down-regulation during angiotensin II-mediated hypertension. Mutation of lysine residues in the C-terminal of ACE2 generates a ubiquitination-resistant mutant (ACE2-5R) with increased activity and resistance to Ang-II-mediated degradation. Expression of ACE2-5R in the bed nucleus of the stria terminalis enhanced GABAergic input to the PVN and reduced hypertension.\",\n      \"method\": \"Bioinformatics, proteomics, in vitro gain/loss-of-function experiments, site-directed mutagenesis, optogenetics, blood pressure telemetry, pharmacological blockade\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — identified E3 ligase by proteomics, validated interaction in vitro, mutagenesis of ubiquitination sites, in vivo functional rescue, multiple orthogonal methods\",\n      \"pmids\": [\"37161607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ACE2 pathway (ACE2/Ang-(1-7)/Mas1 receptor axis) is a critical regulator of thermogenesis and energy expenditure. ACE2 is highly expressed in brown adipose tissue (BAT); cold stimulation increases ACE2 and Ang-(1-7) in BAT and serum. Ace2 knockout and Mas1 knockout mice display impaired thermogenesis. Ace2 pathway activates Akt/FoxO1 and PKA pathways, inducing UCP1 expression and mitochondrial activation. Overexpression of Ace2 or Ang-(1-7) infusion ameliorates impaired thermogenesis in obese mice.\",\n      \"method\": \"Ace2 and Mas1 knockout mice, BAT transplantation, Ace2 overexpression, Ang-(1-7) infusion, pathway analysis (western blotting for Akt/FoxO1, PKA, UCP1)\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models (KO, overexpression), pharmacological rescue, BAT transplantation, mechanistic pathway dissection by western blotting, replicated across multiple models\",\n      \"pmids\": [\"35014608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ACE2 autoantibodies develop after SARS-CoV-2 infection and inhibit ACE2 enzymatic activity. Plasma from patients with ACE2 antibodies inhibits exogenous ACE2 activity in vitro, and these patients have lower soluble ACE2 activity in plasma despite similar ACE2 protein levels.\",\n      \"method\": \"ELISA for ACE2 antibodies, in vitro ACE2 activity inhibition assay using patient plasma\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct functional inhibition assay in vitro, single lab, two orthogonal methods (antibody detection + activity assay)\",\n      \"pmids\": [\"34478478\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ACE2 in breast cancer cells inhibits angiogenesis by downregulating VEGFa expression and inactivating phosphorylation of VEGFR2, MEK1/2, and ERK1/2 in HUVECs. ACE2 also inhibits breast cancer cell migration and metastasis in vivo (zebrafish model).\",\n      \"method\": \"Transwell migration assay, tube formation assay, Western blotting for pathway phosphorylation, zebrafish xenograft model\",\n      \"journal\": \"Journal of experimental & clinical cancer research : CR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro functional assays with downstream pathway analysis and in vivo zebrafish validation, single lab\",\n      \"pmids\": [\"31023337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ACE2 maintains enteral intestinal barrier integrity and reduces diabetic retinopathy (DR) progression through intestinal MasR activation, leading to GSK-3β/c-Myc-mediated decrease in intestinal glucose transporter expression. Genetic overexpression of intestinal ACE2 or oral administration of ACE2-expressing probiotic preserved barrier integrity, reduced inflammation, improved hyperglycemia, and delayed/reversed DR in Akita mice.\",\n      \"method\": \"Genetic intestinal ACE2 overexpression (Vil-Cre.hAce2KI-Akita mice), probiotic oral delivery of ACE2, pathway analysis (MasR, GSK-3β, c-Myc), gut permeability assays, retinal imaging\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic and pharmacological models, defined downstream pathway (MasR/GSK-3β/c-Myc), functional readouts at gut and eye, replicated with independent approaches\",\n      \"pmids\": [\"36448480\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ACE2 interacts with EGFR; SARS-CoV-2 spike protein activates the EGFR-MAPK signaling axis. A cross-talk exists between ACE2 and EGFR that regulates ACE2 abundance and EGFR activation/subcellular localization. Inhibiting EGFR-MAPK activation reduces SARS-CoV-2 infection.\",\n      \"method\": \"Co-immunoprecipitation/proximity assays, EGFR inhibitor treatment, pseudotyped particle and authentic SARS-CoV-2 infection assays, Western blotting\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal interaction demonstrated, functional consequence tested with authentic virus, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"37402592\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ACE2 mRNA and protein expression increase in the border/infarct area after myocardial infarction (MI) in rats. ACE2 protein localizes to macrophages, vascular endothelium, smooth muscle, and myocytes post-MI. Ramipril (ACE inhibitor) had no effect on cardiac ACE2 mRNA, which remained elevated, suggesting independent regulation of ACE2 from ACE. Immunoreactivity of ACE2 was also increased in failing human hearts.\",\n      \"method\": \"Quantitative RT-PCR, immunohistochemistry, in vitro autoradiography, ACE2 activity assays, rat MI model, human failing heart specimens\",\n      \"journal\": \"European heart journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (mRNA, protein, activity), animal model plus human tissue validation, negative result (ACE inhibitor no effect on ACE2) is mechanistically informative\",\n      \"pmids\": [\"15671045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Apelin is a catalytic substrate for ACE2 in addition to angiotensin II. ACE2 cleaves and degrades apelin peptides, forming part of a negative feedback loop in the apelinergic system.\",\n      \"method\": \"Enzymatic substrate assays (in vitro cleavage), referenced in review\",\n      \"journal\": \"International journal of hypertension\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro enzymatic substrate identification referenced in review context, single finding without full methodological detail in abstract\",\n      \"pmids\": [\"25815211\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ACE2 is a carboxypeptidase that degrades angiotensin II, B1-bradykinin, and apelin, acting as a critical regulator of cardiovascular physiology. Both SARS-CoV-2 and SARS coronaviruses downregulate ACE2 expression upon infection, contributing to ARDS pathogenesis.\",\n      \"method\": \"Review of enzymatic substrate characterization studies, genetic animal models with ARDS phenotype readout\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — enzymatic substrate diversity established across multiple independent labs, ARDS protective role in genetic models\",\n      \"pmids\": [\"35003058\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ACE2 expression and activity are significantly enhanced during pregnancy, with placentas being the major contributors followed by kidney and uterus. Total ACE2 activity increases approximately twofold in pregnancy, consistent with a role in modulating systemic and local uteroplacental hemodynamics.\",\n      \"method\": \"Quantitative RT-PCR for mRNA, enzymatic activity assays, normotensive and hypertensive rat pregnancy model\",\n      \"journal\": \"American journal of physiology. Regulatory, integrative and comparative physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative mRNA and activity measurements in animal model, single lab with two orthogonal methods\",\n      \"pmids\": [\"18945956\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ACE2 is a zinc-dependent monocarboxypeptidase ectoenzyme (type I transmembrane glycoprotein) with an HEMGH zinc-binding motif that cleaves angiotensin II to the vasodilatory angiotensin-(1-7), angiotensin I to Ang 1-9, and also degrades apelin and B1-bradykinin; it is insensitive to classical ACE inhibitors, heterodimerizes with intestinal amino acid transporters (B0AT1/SLC6A19) to regulate their surface expression and neutral amino acid absorption, is tethered at the plasma membrane via interaction of its C-terminal PDZ motif with NHERF1, is ubiquitinated and degraded by the E3 ligase Nedd4-2 (promoted by angiotensin II), and is transcriptionally repressed by EZH2-mediated H3K27me3 at its promoter; it localizes prominently to airway motile cilia, proximal tubular epithelium, brown adipose tissue, and hypothalamic GABAergic neurons where it supports inhibitory tone to presympathetic nuclei; the ACE2/Ang-(1-7)/Mas receptor axis counterbalances the classical ACE/Ang II/AT1R axis in cardiovascular, renal, pulmonary, intestinal, and metabolic homeostasis (including thermogenesis via Akt/FoxO1 and PKA/UCP1 pathways), and serves as the obligate entry receptor for SARS-CoV, SARS-CoV-2, and HCoV-NL63, with viral binding inducing clathrin/AP2-dependent endocytosis and lysosomal degradation of ACE2.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ACE2 is a zinc-dependent monocarboxypeptidase ectoenzyme that anchors a protective arm of the renin-angiotensin system, counterbalancing the classical ACE/Ang II axis across cardiovascular, renal, intestinal, and metabolic tissues [#0, #18]. Its single catalytic domain carries an HEMGH zinc-binding motif and cleaves angiotensin I to Ang 1-9 and angiotensin II to the vasodilatory angiotensin-(1-7), while remaining insensitive to classical ACE inhibitors; it additionally degrades apelin and B1-bradykinin [#0, #17, #18]. The ACE2/Ang-(1-7)/Mas1 axis drives downstream physiology in several settings: it activates Akt/FoxO1 and PKA signaling to induce UCP1 and brown-adipose thermogenesis [#11], maintains intestinal barrier integrity and limits diabetic retinopathy through intestinal MasR/GSK-3β/c-Myc signaling [#14], and in hypothalamic PVN GABAergic neurons supports inhibitory tone to presympathetic neurons, restraining blood pressure [#6]. As a type I transmembrane glycoprotein, ACE2 is a chimera of an ACE-like catalytic domain and a collectrin-like C-terminal domain, and it heterodimerizes with neutral amino acid transporters B0AT1/SLC6A19 (and SIT1/SLC6A20) to control their surface expression and neutral amino acid absorption [#0, #3, #5]. Its membrane abundance is set post-translationally: a C-terminal PDZ-recognition motif binds the scaffold NHERF1 to tether ACE2 at the surface [#9], the E3 ligase Nedd4-2 ubiquitinates C-terminal lysines to drive angiotensin II-promoted degradation [#10], and the gene is transcriptionally repressed by EZH2-mediated H3K27me3 at its promoter [#7]. ACE2 robustly localizes to airway motile cilia and serves as the obligate entry receptor for SARS-CoV, SARS-CoV-2, and NL63 coronaviruses; viral binding triggers clathrin/AP2-dependent endocytosis and lysosomal degradation of ACE2, and a soluble ACE2 fragment blocks both down-regulation and infection [#1, #4, #8].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Established ACE2 as a distinct zinc carboxypeptidase that processes angiotensin peptides but, unlike ACE, is insensitive to ACE inhibitors and does not cleave bradykinin, defining a separate enzymatic arm of the renin-angiotensin system.\",\n      \"evidence\": \"Cloning, functional expression, in vitro enzymatic assays, and domain analysis\",\n      \"pmids\": [\"12025971\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the in vivo physiological consequence of Ang 1-7 generation\", \"Substrate repertoire beyond angiotensin peptides not yet defined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showed ACE2 is dynamically regulated and induced in injured myocardium independently of ACE, indicating a tissue-level cardiac protective response distinct from the classical pathway.\",\n      \"evidence\": \"RT-PCR, immunohistochemistry, activity assays in rat MI model and human failing hearts\",\n      \"pmids\": [\"15671045\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of transcriptional induction after injury not identified\", \"Causal contribution of induced ACE2 to repair vs. fibrosis untested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Determined the ACE2 crystal structure and confirmed via genetic models its dual role as Ang II carboxypeptidase and coronavirus receptor, unifying enzymatic and viral-entry functions on one protein.\",\n      \"evidence\": \"Crystal structure determination plus knockout/knock-in mouse models and enzymatic assays\",\n      \"pmids\": [\"17464936\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of regulated surface trafficking not addressed\", \"Did not connect receptor and enzymatic roles mechanistically\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Demonstrated physiological up-regulation of ACE2 expression and activity in pregnancy, implicating it in uteroplacental hemodynamic adaptation.\",\n      \"evidence\": \"RT-PCR and enzymatic activity in normotensive and hypertensive rat pregnancy models\",\n      \"pmids\": [\"18945956\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signal driving pregnancy-associated induction unknown\", \"Human placental relevance inferred from rat model\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined a non-enzymatic chaperone function: ACE2 heterodimerizes with B0AT1 (and collectrin with B0AT3 in kidney) to enable transporter surface expression, linking ACE2 to neutral amino acid absorption and Hartnup-disorder pathology.\",\n      \"evidence\": \"Protein interaction and surface expression assays with tissue-specific analysis\",\n      \"pmids\": [\"21814048\", \"20134095\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Stoichiometry and structural basis of the heterodimer not resolved at this stage\", \"Whether catalytic activity contributes to transport unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Placed ACE2 within central blood-pressure control, showing PVN GABAergic neuronal ACE2 sustains inhibitory tone to presympathetic neurons and restrains hypertension, with ADAM17 shedding opposing this.\",\n      \"evidence\": \"Conditional neuron-specific knockout mice, neuron cultures, photoactivation, BP telemetry, pharmacological blockade\",\n      \"pmids\": [\"31564162\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Local peptide signaling (Ang-(1-7)/Mas) linking ACE2 to GABA tone not directly traced\", \"Which downstream effectors set GABAergic strength unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Revealed an anti-angiogenic, anti-metastatic role for ACE2 in breast cancer via suppression of VEGFa/VEGFR2-MEK-ERK signaling, extending ACE2 function beyond cardiovascular and viral contexts.\",\n      \"evidence\": \"Migration and tube-formation assays, pathway Western blotting, zebrafish xenograft\",\n      \"pmids\": [\"31023337\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether the effect requires enzymatic activity or Ang-(1-7)/Mas signaling untested\", \"Single zebrafish in vivo model\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Localized ACE2 protein to airway motile cilia of upper and lower respiratory epithelium, identifying the initial subcellular site of SARS-CoV-2 entry and showing ACE inhibitors/ARBs do not raise ciliary ACE2.\",\n      \"evidence\": \"Immunofluorescence, multiplex imaging, and IHC across a diverse human tissue panel\",\n      \"pmids\": [\"33116139\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism targeting ACE2 to the ciliary membrane not defined\", \"Functional contribution of ciliary localization to enzymatic role unaddressed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified epigenetic repression of ACE2, with EZH2-mediated H3K27me3 silencing the promoter and EZH2 loss de-repressing ACE2, establishing a chromatin-level control of receptor/enzyme abundance.\",\n      \"evidence\": \"EZH2 knockout in hESCs with RNA-seq and ChIP-seq\",\n      \"pmids\": [\"32291076\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological signals modulating EZH2 occupancy at ACE2 unknown\", \"Relevance in differentiated airway/intestinal cells not shown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed ACE2-B0AT1/SIT1 heterodimers assemble quaternary structures that present spike-binding surfaces, integrating the amino-acid-transport partnership with coronavirus recognition.\",\n      \"evidence\": \"Co-IP, structural studies, viral binding assays\",\n      \"pmids\": [\"33140827\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether transporter association modulates infection in vivo untested\", \"Single-lab structural interpretation\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined post-translational control of ACE2 surface residence: direct binding of the ACE2 C-terminal PDZ motif to both NHERF1 PDZ domains tethers ACE2 at the membrane and tunes viral entry.\",\n      \"evidence\": \"Co-IP, proximity ligation in human lung/intestine cells, PDZ-motif mutagenesis, pseudovirus entry assays\",\n      \"pmids\": [\"34189428\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How NHERF1 binding is dynamically regulated by physiological signals unknown\", \"Interplay between NHERF1 tethering and Nedd4-2 degradation not jointly resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed post-infection ACE2 autoantibodies functionally inhibit ACE2 enzymatic activity, providing an acquired-immunity route to suppress the protective ACE2 axis.\",\n      \"evidence\": \"ELISA for ACE2 antibodies and in vitro plasma inhibition assays\",\n      \"pmids\": [\"34478478\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Epitope and mechanism of catalytic inhibition undefined\", \"In vivo physiological consequence not established\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Connected ACE2 to whole-body energy balance, demonstrating the ACE2/Ang-(1-7)/Mas1 axis drives brown-fat thermogenesis through Akt/FoxO1 and PKA pathways inducing UCP1.\",\n      \"evidence\": \"Ace2 and Mas1 knockout mice, BAT transplantation, Ace2 overexpression, Ang-(1-7) infusion, pathway Western blotting\",\n      \"pmids\": [\"35014608\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How cold stimulus induces ACE2 in BAT not mechanistically traced\", \"Relative contribution of local vs. systemic Ang-(1-7) unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrated an intestinal ACE2 gut-eye axis, where intestinal ACE2/MasR signaling via GSK-3β/c-Myc preserves barrier integrity and delays diabetic retinopathy.\",\n      \"evidence\": \"Intestinal ACE2 overexpression and ACE2-probiotic delivery in Akita mice, pathway analysis, permeability and retinal imaging\",\n      \"pmids\": [\"36448480\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mediators linking gut barrier to retinal protection not fully defined\", \"Whether glucose-transporter downregulation is the sole effector unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Mechanistically dissected SARS-CoV-2-induced ACE2 down-regulation, showing clathrin/AP2-dependent endocytosis and lysosomal degradation drive loss of ACE2 and pathogenic cytokine signaling, blockable by soluble ACE2.\",\n      \"evidence\": \"In vivo infection model, cell culture, siRNA knockdown, gene-expression profiling, endocytosis inhibitor studies\",\n      \"pmids\": [\"36287912\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Adaptor coupling spike binding to AP2 recruitment not pinpointed\", \"Contribution of lost enzymatic vs. transporter function to disease not separated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified Nedd4-2 as the E3 ligase ubiquitinating ACE2 C-terminal lysines during Ang II hypertension; a ubiquitination-resistant ACE2-5R mutant resists degradation and lowers blood pressure when expressed in the BNST, defining a feedback loop coupling Ang II to ACE2 turnover.\",\n      \"evidence\": \"Proteomics, in vitro gain/loss-of-function, site-directed mutagenesis, optogenetics, BP telemetry\",\n      \"pmids\": [\"37161607\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling that activates Nedd4-2 toward ACE2 upon Ang II not fully traced\", \"Interaction with NHERF1 tethering in setting turnover not co-analyzed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Revealed reciprocal ACE2-EGFR cross-talk in which ACE2 binds EGFR and spike-driven EGFR-MAPK activation regulates ACE2 abundance and supports infection, linking ACE2 to growth-factor signaling.\",\n      \"evidence\": \"Co-IP/proximity assays, EGFR inhibition, pseudotyped and authentic SARS-CoV-2 infection, Western blotting\",\n      \"pmids\": [\"37402592\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs. indirect nature of the ACE2-EGFR interaction not fully resolved\", \"Single-lab study\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the multiple layers controlling ACE2 abundance — NHERF1 tethering, Nedd4-2 ubiquitination, EZH2 repression, endocytic degradation, and EGFR cross-talk — are integrated to set tissue-specific ACE2 levels during physiology and infection remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model coordinating transcriptional, trafficking, and degradative control\", \"Quantitative contribution of each layer in different tissues unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 17, 18]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 18]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [1, 2, 8]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [1, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [9, 3, 5]},\n      {\"term_id\": \"GO:0005929\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [6, 11, 14]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [8, 18]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [11, 14]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"complexes\": [\n      \"ACE2-B0AT1 (SLC6A19) heterodimer\",\n      \"ACE2-SIT1 (SLC6A20) heterodimer\"\n    ],\n    \"partners\": [\n      \"SLC6A19\",\n      \"SLC6A20\",\n      \"NHERF1\",\n      \"NEDD4L\",\n      \"EGFR\",\n      \"TMEM27\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}